# Scheduling Nab-paclitaxel With Gemcitabine

> **NCT03529175** · PHASE2 · COMPLETED · sponsor: **CCTU- Cancer Theme** · enrollment: 146 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma Metastatic

## Interventions

- **DRUG:** Abraxane (nab-paclitaxel)
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT03529175
- **Lead sponsor:** CCTU- Cancer Theme
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2019-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03529175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03529175, "Scheduling Nab-paclitaxel With Gemcitabine". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03529175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*